CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $192.64M, lower than 95% of all stocks globally
- PositionReturn on equity is -209.3%, lower than 95% of its Biotechnology peers (median -21.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
192.64MUSDvs all stocks (USD)
Revenue (TTM)
3.93MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
133.33%vs all stocks
Market Capitalization
192.64MUSDvs all stocks (USD)
Enterprise Value
121.52MUSDvs all stocks (USD)
Forward P/E
-5.01xvs Biotechnology peers
Price to Sales (TTM)
51.48xvs Biotechnology peers
Price to Book (MRQ)
6.55xvs Biotechnology peers
Enterprise to Revenue
30.89xvs Biotechnology peers
Enterprise to EBITDA
-2.42xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1010.12%vs Biotechnology peers
Return on Assets (TTM)
-38.66%vs Biotechnology peers
Return on Equity (TTM)
-209.28%vs Biotechnology peers
Revenue (TTM)
3.93MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0990USDUpdated Jul 18, 2026Quarterly Revenue Growth
50.80%vs Biotechnology peers
Gross Profit (TTM)
-34.28MUSDvs all stocks (USD)
EBITDA (TTM)
-50.29MUSDvs all stocks (USD)
Net Income (TTM)
-86.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
50.82%vs Biotechnology peers
Operating Cash Flow (TTM)
-26.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.80MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.50MUSDFY2025 · Dec 31, 2025Operating Income
-52.06MUSDvs all stocks (USD)
Pre-tax Income
-80.40MUSDFY2025 · Dec 31, 2025Net Income
-80.40MUSDFY2025 · Dec 31, 2025EBIT
-52.06MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.10MUSDFY2025 · Dec 31, 2025Research & Development
38.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.36MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-80.40MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-60.05MUSDFY2025 · Dec 31, 2025Free Cash Flow
-60.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
111.76MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-80.40MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.64MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.62MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.03MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
14.12MUSDFY2025 · Dec 31, 2025Capital Expenditures
-243.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-243.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-111.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
14.83MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
72.24MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.93MSharesUpdated Jul 18, 2026Float Shares
27.47MSharesUpdated Jul 18, 2026Shares Short
1.31MSharesUpdated Jul 18, 2026Short Ratio
4.21daysvs all stocks
Short % of Shares Outstanding
3.73%vs all stocks
% Held by Insiders
13.07%vs all stocks
% Held by Institutions
86.72%vs all stocks
Total Cash (MRQ)
99.21MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.91USDUpdated Jul 18, 2026Total Debt (MRQ)
2.12MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0687xvs Biotechnology peers
Current Ratio (MRQ)
6.15xvs Biotechnology peers
Book Value per Share (MRQ)
0.5950USDUpdated Jul 18, 2026Total Assets
117.81MUSDvs all stocks (USD)
Total Current Assets
114.09MUSDFY2025 · Dec 31, 2025Total Liabilities
70.10MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.71MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
54.59MUSDFY2025 · Dec 31, 2025Total Current Liabilities
15.51MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
109.52MUSDFY2025 · Dec 31, 2025Accounts Payable
182.00KUSDFY2025 · Dec 31, 2025Short-term Debt
286.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
9.39MUSDFY2025 · Dec 31, 2025Other Current Liabilities
116.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.69MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
29.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-292.16MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
47.70MUSDvs all stocks (USD)
52-Week Low
1.32USDUpdated Jul 18, 202652-Week High
7.75USDUpdated Jul 18, 202652-Week Change
133.33%vs all stocks
50-Day MA
4.26USDUpdated Jul 18, 2026200-Day MA
4.41USDUpdated Jul 18, 2026Avg 10-Day Volume
157.11KSharesUpdated Jul 18, 2026Avg 30-Day Volume
269.48KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.35USDUpdated Jul 18, 2026Other Income / Expense
-30.52MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -209.3%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.09Industry median: -0.22Industry P5: -1.66Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.15Altman Z-Score: -2.25
Financial Health
Altman Z-Score -2.25: distress zoneCritical
Altman Z-Score: -2.25
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $192.64M, lower than 95% of all stocks globallySignificant
Market cap (USD): 192,644,718Global P5: 269,387,740.27
Revenue is $3.93M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,934,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk